Edition:
United Kingdom

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.29EUR
16 Nov 2018
Change (% chg)

€-0.01 (-3.00%)
Prev Close
€0.30
Open
€0.30
Day's High
€0.30
Day's Low
€0.29
Volume
222,170
Avg. Vol
1,911,302
52-wk High
€0.60
52-wk Low
€0.25

Latest Key Developments (Source: Significant Developments)

Molmed SpA reports Qtrly Revenue Of EUR 7,202 Thousands
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Molecular Medicine SpA ::OPERATING REVENUES, AS OF SEPTEMBER 30TH 2018, ARE EQUAL TO EURO 20,012 THOUSANDS, UP 27.9% COMPARED TO FIRST NINE MONTHS OF 2017.QTRLY REVENUE OF EUR 7,202 THOUSANDS VERSUS EUR 6,001 THOUSANDS.MOLMED- AS OF SEPT 30, 2018, OPERATING RESULT AND NET RESULT RESPECTIVELY EQUAL TO LOSS OF EURO 4.6 MILLION AND EURO 4.9 MILLION RESPECTIVELY.  Full Article

Molmed, Dompé Announce Mutual Termination Of License And Distribution Agreement For Zalmoxis
Monday, 12 Nov 2018 

Nov 12 (Reuters) - :MOLMED AND DOMPÉ ANNOUNCE MUTUAL TERMINATION OF LICENSE AND DISTRIBUTION AGREEMENT FOR ZALMOXIS.MOLMED SAYS ORDER TO ENSURE CONTINUITY OF ONGOING ACTIVITIES, DOMPÉ WILL SUPPORT CO IN TRANSITION PHASE THAT IS EXPECTED TO BE COMPLETED BY EARLY 2019.MOLMED SAYS GAINS BACK PRODUCT MARKETING RIGHTS TO RE-START COMMERCIAL DEVELOPMENT.MOLMED SAYS RECEIVES FROM DOMPÉ 100% OF DEFERRED CONTRIBUTION CONTRACTUALLY FORESEEN FOR YEAR 2018.MOLMED SAYS AS PART OF TERMINATION AGREEMENT, DOMPÉ WILL PAY EURO 3 MILLION TO CO, WHICH CORRESPONDS TO 100% OF DEFERRED CONTRIBUTION STILL DUE TO CO FOR FY 2018.  Full Article

MolMed Signs Agreement For Development And Supply Of Lentiviral Vectors
Friday, 13 Jul 2018 

(Reuters) - MolMed ::SAID ON FRIDAY SIGNED A NEW, THREE-YEAR AGREEMENT FOR THE DEVELOPMENT AND SUPPLY OF LENTIVIRAL VECTORS.MOLMED WILL PROVIDE GSK WITH VECTORS FOR THE ONCOLOGY FIELD.  Full Article

MolMed Q1 Net Loss Narrows to EUR 1.2 Mln
Friday, 11 May 2018 

May 14 (Reuters) - MolMed ::REPORTED ON FRIDAY Q1 NET LOSS OF EUR 1.2 MLN VS LOSS EUR 3.7 MLN YEAR AGO.Q1 OPERATING REVENUE OF EUR 5.8 MLN VS EUR 4.4 MLN YEAR AGO.  Full Article

MolMed Starts Collaboration With Orchard Therapeutics For Rare Diseases
Thursday, 12 Apr 2018 

April 12 (Reuters) - Molecular Medicine SpA ::STARTS COLLABORATION WITH ORCHARD THERAPEUTICS ON GENE THERAPY FOR RARE DISEASES.  Full Article

Molmed FY Net Loss Shrinks To EUR 8.5 Mln
Friday, 9 Mar 2018 

March 12 (Reuters) - MOLMED SPA ::REPORTED ON FRIDAY FY TOTAL OPERATING REVENUES EUR 24.0 MLN VS EUR 22.8 MLN YEAR AGO.FY NET LOSS EUR 8.5 MLN VS LOSS EUR 13.9 MLN YEAR AGO.  Full Article

MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - MOLECULAR MEDICINE SPA ::SAYS THAT AS OF JAN 15 ZALMOXIS CAN BE PRESCRIBED AND REIMBURSED IN GERMANY AT THE PRICE OF EUR 163,900 PER INFUSION.APPROVED DOSAGE FORESEES ONE OR MORE INFUSIONS, UP TO A MAXIMUM OF FOUR, TILL IMMUNE-RECONSTITUTION IS ACHIEVED.MOLMED WILL BE RESPONSIBLE FOR THE PRODUCTION AND SUPPLY OF ZALMOXIS, WHILE DOMPÉ FARMACEUTICI WILL CONDUCT ACTIVITIES AIMED AT MARKETING THE THERAPY IN GERMANY.DOMPÉ WILL PAY MOLMED A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT.  Full Article

Molmed Q3 net loss narrows to EUR 1.6‍​ mln
Monday, 6 Nov 2017 

Nov 6 (Reuters) - MOLECULAR MEDICINE SPA ::Q3 OPERATING REVENUE EUR ‍​6.2 MILLION VERSUS EUR 3.7 MILLION YEAR AGO.Q3 NET LOSS EUR 1.6‍​ MILLION VERSUS LOSS EUR 5.9 MILLION YEAR AGO.  Full Article

Italy - Factors to watch on Nov. 12

The following factors could affect Italian markets on Monday.